We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Theravance (TBPH) Q3 Loss In Line, Revenues Lag Estimates
Read MoreHide Full Article
Theravance Biopharma, Inc. (TBPH - Free Report) incurred a loss of $1.05 per share in third-quarter 2019, in line with the Zacks Consensus Estimate. Meanwhile, the figure is narrower than the year-ago quarter’s loss of $1.10.
However, total revenues of $12.4 million in the quarter missed the Zacks Consensus Estimate of $13 million. Revenues also decreased 3.1% year over year, mainly due to lack of product sales following the divesture of its only marketed drug Vibativ to Cumberland Pharmaceuticals last November. Total revenues in the third quarter comprised collaboration revenues of $8.8 million and $3.6 million received from Mylan .
Theravance has collaboration with Mylan for the development and commercialization of Yupelri (revefenacin), which was approved by the FDA last November. The drug is used for maintenance treatment of adults with chronic obstructive pulmonary disease (COPD).
Per the press release, Yupelri witnessed strong customer acceptance and brand performance across key market metrics in the third quarter.
Shares of Theravance have lost 33.1% in the year so far versus the industry’s growth of 4.3%.
Quarter in Detail
Research & development expenses were $52 million, down 1.3% from the year-ago quarter, primarily owing to lower employee-related expenses linked with the reduction in sales force.
Selling, general & administrative expenses escalated 16.9% to $25.6 million due to higher external expenses and higher share-based compensation.
As of Sep 30, 2019, Theravance had cash, cash equivalents, marketable securities and restricted cash of $352.9 million compared to $396.1 million as of Jun 30, 2019.
Product & Pipeline Updates
Notably, Theravance has an economic interest in royalties earned from GlaxoSmithKline (GSK - Free Report) on triple combination COPD treatment Trelegy Ellipta’s global sales. In the third quarter, Glaxo recorded sales of $172.8 million from Trelegy Ellipta. Theravance is eligible to receive 5.5-8.5% (tiered) of the product's worldwide net sales.
The company also has a collaboration agreement with Johnson & Johnson’s (JNJ - Free Report) subsidiary Janssen to develop its JAK inhibitor TD-1473 for the treatment of inflammatory intestinal diseases. A phase II study on TD-1473 for treating Crohn's disease and a phase IIb/III study for ulcerative colitis are ongoing. Data from the phase IIb portion of the ulcerative colitis and phase II Crohn's disease studies are expected in late 2020.
Theravance is evaluating ampreloxetine (TD-9855) in a phase III program for treating patients with symptomatic neurogenic orthostatic hypotension (nOH).
The company is developing inhaled, lung-selective pan-Janus kinase (JAK) inhibitor TD-8236 in a phase I study for the treatment of inflammatory lung diseases with minimal systemic exposure. In September 2019, Theravance announced promising outcomes from a phase I study on TD-8236, having evaluated it in single ascending doses (up to 4500 mcg) and multiple ascending doses (up to 4000 mcg).
Theravance is also developing its gut-selective irreversible JAK3 inhibitor TD-5202 in a phase I study for addressing inflammatory intestinal diseases.
2019 Outlook
For 2019, Theravance anticipates operating loss excluding non-cash share-based compensation to be in the range of $200-$210 million, narrowed from the previous guidance of $210-$230 million.
Theravance Biopharma, Inc. Price, Consensus and EPS Surprise
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
Theravance (TBPH) Q3 Loss In Line, Revenues Lag Estimates
Theravance Biopharma, Inc. (TBPH - Free Report) incurred a loss of $1.05 per share in third-quarter 2019, in line with the Zacks Consensus Estimate. Meanwhile, the figure is narrower than the year-ago quarter’s loss of $1.10.
However, total revenues of $12.4 million in the quarter missed the Zacks Consensus Estimate of $13 million. Revenues also decreased 3.1% year over year, mainly due to lack of product sales following the divesture of its only marketed drug Vibativ to Cumberland Pharmaceuticals last November. Total revenues in the third quarter comprised collaboration revenues of $8.8 million and $3.6 million received from Mylan .
Theravance has collaboration with Mylan for the development and commercialization of Yupelri (revefenacin), which was approved by the FDA last November. The drug is used for maintenance treatment of adults with chronic obstructive pulmonary disease (COPD).
Per the press release, Yupelri witnessed strong customer acceptance and brand performance across key market metrics in the third quarter.
Shares of Theravance have lost 33.1% in the year so far versus the industry’s growth of 4.3%.
Quarter in Detail
Research & development expenses were $52 million, down 1.3% from the year-ago quarter, primarily owing to lower employee-related expenses linked with the reduction in sales force.
Selling, general & administrative expenses escalated 16.9% to $25.6 million due to higher external expenses and higher share-based compensation.
As of Sep 30, 2019, Theravance had cash, cash equivalents, marketable securities and restricted cash of $352.9 million compared to $396.1 million as of Jun 30, 2019.
Product & Pipeline Updates
Notably, Theravance has an economic interest in royalties earned from GlaxoSmithKline (GSK - Free Report) on triple combination COPD treatment Trelegy Ellipta’s global sales. In the third quarter, Glaxo recorded sales of $172.8 million from Trelegy Ellipta. Theravance is eligible to receive 5.5-8.5% (tiered) of the product's worldwide net sales.
The company also has a collaboration agreement with Johnson & Johnson’s (JNJ - Free Report) subsidiary Janssen to develop its JAK inhibitor TD-1473 for the treatment of inflammatory intestinal diseases. A phase II study on TD-1473 for treating Crohn's disease and a phase IIb/III study for ulcerative colitis are ongoing. Data from the phase IIb portion of the ulcerative colitis and phase II Crohn's disease studies are expected in late 2020.
Theravance is evaluating ampreloxetine (TD-9855) in a phase III program for treating patients with symptomatic neurogenic orthostatic hypotension (nOH).
The company is developing inhaled, lung-selective pan-Janus kinase (JAK) inhibitor TD-8236 in a phase I study for the treatment of inflammatory lung diseases with minimal systemic exposure. In September 2019, Theravance announced promising outcomes from a phase I study on TD-8236, having evaluated it in single ascending doses (up to 4500 mcg) and multiple ascending doses (up to 4000 mcg).
Theravance is also developing its gut-selective irreversible JAK3 inhibitor TD-5202 in a phase I study for addressing inflammatory intestinal diseases.
2019 Outlook
For 2019, Theravance anticipates operating loss excluding non-cash share-based compensation to be in the range of $200-$210 million, narrowed from the previous guidance of $210-$230 million.
Theravance Biopharma, Inc. Price, Consensus and EPS Surprise
Theravance Biopharma, Inc. price-consensus-eps-surprise-chart | Theravance Biopharma, Inc. Quote
Zacks Rank
Theravance currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>